Mato just raised pre-seed Read more
Podcast charts
Published by Nataliya Andreychuk
Join Nataliya Andreychuk, CEO of Viseven, on Pharma Talks – a podcast where human voices meet industry insights. Dive into engaging conversations with industry leaders, exploring the latest trends in pharma marketing, digital transformation, and AI-driven solutions. 🔗 Follow Nataliya on LinkedIn for more updates and insights: https://www.linkedin.com/in/andreychuk/ 🔗 Discover more about Viseven's digital solutions at viseven.com
On the charts
Every published chart this podcast appears in, in the snapshot behind this page. Each one links to the chart it came off.
The Mato Topic Intelligence Platform does not report this podcast as charting in a published category in this snapshot.
From the feed
The latest episodes published to this podcast’s own RSS feed. Titles and descriptions are the publisher’s.
In this solo episode of Pharma Talks, Nataliya Andreychuk takes an unfiltered look at one of the biggest challenges emerging from AI adoption in the pharmaceutical industry: the velocity trap. Pharma is investing billions in artificial intelligence, accelerating content production, expanding into new channels, and making localization easier than ever. Yet at the same time, huge volumes of approved content are never used. Nataliya explores what happens when AI-powered content creation moves faster than the workflows, relationships, and human expertise needed to make that content meaningful. She looks at the gap between content production and HCP engagement, the role of AI-native pharma organizations, and why AI may be exposing — rather than solving — broken pharmaceutical content workflows. The conversation also introduces the HUMICS framework and explores the uniquely human capabilities that will become even more important in an AI-native pharmaceutical organization. 00:00 Welcome to a solo episode of Pharma Talks 00:07 Pharma’s massive AI investment and the race for efficiency 02:00 The AI content “velocity trap” 04:00 Why more content doesn’t necessarily mean more engagement 06:00 AI-native pharma and the future of human expertise 08:00 The HUMICS framework 10:00 Human-in-the-loop, MLR and compliant AI 12:00 The AI roadmap pharma leaders should be building 📲 Enjoyed this episode? 👉 Like, Subscribe & hit the 🔔 to never miss a Pharma Talks episode 👉 Want to be a guest? Plan your recording with Nataliya Andreychuk. 🔗 Follow & Connect: 🎙️ Nataliya Andreychuk → https://www.linkedin.com/in/andreychuk/
Steve Swan returns to Pharma Talks for a conversation about what has changed in pharma talent and recruitment since his last conversation with Nataliya Andreychuk a year ago. And the answer is: a lot. AI is now writing job descriptions, tailoring resumes, screening candidates — and, in some cases, essentially creating an AI-versus-AI recruitment loop. The result? Hundreds of polished applications, but not necessarily more people who can actually do the job. With nearly 30 years of experience hiring across pharma and biotech, Steve shares what he is seeing from the front lines — from the growing demand for AI talent to the rise of "AI-native" professionals and the new role of humans in an increasingly AI-driven workplace. Chapters: 0:00 AI is already changing recruitment 4:13 The AI recruitment loop: when AI starts checking its own homework 11:37 Are AI-native professionals the next generation of pharma talent? 15:05 The "bionic employee" and why human intelligence still matters 19:38 Hot or Not: Is pharma already losing the AI talent race? 24:32 Can pharma compete with Big Tech for AI talent? 25:06 Where will the next pharma talent wave come from? 📲 Enjoyed this episode? 👉 Like, subscribe & hit the 🔔 to never miss a Pharma Talks episode. 👉 Have a question about hiring, recruiting or building AI talent in pharma and biotech? Send it our way — we're listening. 🔗 Follow & Connect: 🎙️ Nataliya Andreychuk → https://www.linkedin.com/in/andreychuk/ 🎙️ Steve Swan → https://www.linkedin.com/in/swangroup/
Part 2 of this Pharma Talks conversation with Elaine Gamble moves from identifying the challenges of Commercial and Medical collaboration to the practical steps organizations can take to create connected customer experiences. The discussion explores how AI, next best action, customer data, and organizational culture can help pharma teams work as one — without compromising compliance or scientific integrity. 📲 Enjoyed this episode? 👉 Like, Subscribe & hit the 🔔 to never miss a Pharma Talks episode. 👉 Want to be a guest? Plan your recording with Nataliya Andreychuk. 🔗 Follow & Connect: 🎙️ Nataliya Andreychuk → https://www.linkedin.com/in/andreychuk/ 🎙️ Elaine Gamble → https://www.linkedin.com/in/elainegamble/
Elaine Gamble, customer engagement leader, omnichannel strategist, and former executive at Merck, Novartis, Otsuka, and other leading pharmaceutical companies, joins Nataliya Andreychuk on Pharma Talks to explore why stronger collaboration between Commercial and Medical has become essential for delivering connected, compliant, and customer-centric engagement. In Part 1, Elaine explains why silos still exist despite years of digital transformation—and why technology isn't the biggest barrier. Key takeaways: Commercial and Medical teams often share the same goals but operate through transactional relationships instead of true collaboration. Leadership, culture, and shared initiatives — not incentives alone — are the foundation of effective cross-functional alignment. MSL insights remain one of pharma's most underutilized assets and can significantly improve commercial engagement when shared appropriately. AI, orchestration, and omnichannel capabilities already exist to support collaboration — but many organizations are still underusing them. The future of customer engagement depends on seeing one healthcare professional through one connected customer journey. Discover how leading pharma organizations can move beyond silos and build stronger Commercial and Medical partnerships that create more meaningful healthcare professional experiences. Explore why pharma needs stronger Commercial and Medical collaboration to deliver connected, compliant, and customer-centric engagement. 📲 Enjoyed this episode? 👉 Like, Subscribe & hit the 🔔 to never miss a Pharma Talks episode. 👉 Want to be a guest? Plan your recording with Nataliya Andreychuk. 🔗 Follow & Connect: 🎙️ Nataliya Andreychuk → https://www.linkedin.com/in/andreychuk/ 🎙️ Elaine Gamble → https://www.linkedin.com/in/elainegamble/
Part 2 of this Pharma Talks conversation with Matteo Colonna picks up where strategy meets execution — moving from the "why" of omnichannel and AI to the practical realities of making it work inside pharma organizations. 📲 Enjoyed this episode? 👉 Like, Subscribe & hit the 🔔 to never miss a Pharma Talks episode 👉 Want to be a guest? Plan your recording with Nataliya Andreychuk 🔗 Follow & Connect: 🎙️ Nataliya Andreychuk → https://www.linkedin.com/in/andreychuk/ 🎙️ Matteo Colonna → https://www.linkedin.com/in/colonnamatteo/
Matteo Colonna, an omnichannel transformation practitioner with a background in theoretical physics from Sapienza University in Rome and experience across consulting, digital agencies, and two major pharma companies, joins Nataliya Andreychuk on Pharma Talks to unpack why omnichannel and AI have moved from "nice to have" to business necessity. Key takeaways: Customer behavior and expectations have fundamentally shifted — pharma companies can no longer design omnichannel experiences without first understanding what customers actually need and prefer. Technology should never be the starting point — the right approach begins with identifying the business or customer problem, then working backward to the technology that solves it. Omnichannel and AI transformation is no longer a technology project — it's a full business transformation that touches strategy, structure, and mindset. Real omnichannel execution requires bridging strategy and day-to-day operations, not just designing frameworks on paper. Explore how pharma teams move from omnichannel strategies to execution and where AI creates real value across content, insights, and engagement. 📲 Enjoyed this episode? 👉 Like, Subscribe & hit the 🔔 to never miss a Pharma Talks episode 👉 Want to be a guest? Plan your recording with Nataliya Andreychuk 🔗 Follow & Connect: 🎙️ Nataliya Andreychuk → https://www.linkedin.com/in/andreychuk/ 🎙️ Matteo Colonna → https://www.linkedin.com/in/colonnamatteo/
Karol Wolak, Director and Global Omnichannel Excellence Lead at Merck, joins Nataliya Andreychuk on Pharma Talks to tackle a question on everyone's mind: is AI coming for pharma jobs? His perspective is grounded in hands-on work across customer engagement and digital transformation at one of the industry's largest organizations. Views shared are Karol Wolak's own and do not represent an official position of Merck. Key takeaways: AI isn't replacing pharma roles anytime soon — it's better positioned to absorb repetitive back-office work like content tagging, MLR approval, and data collection. Human qualities — context, ethics, judgment, empathy — remain outside what AI can deliver, especially in a highly regulated industry. The environmental cost of AI, from data storage to energy consumption, is a factor the industry rarely puts on the table. Patient-centricity stays the anchor point for every engagement decision, regardless of which technology sits behind it. Staying engaged and experimenting with AI beats waiting on the sidelines — but balance matters more than volume. Chapters: 0:00 Cold open — "AI will not replace us, at least not now" 0:51 Karol Wolak on the shift from multichannel to omnichannel at Merck 1:49 Why patients are the real center of pharma engagement 3:33 Does AI take our jobs? The blunt answer 5:02 Resource optimization: where AI actually helps pharma teams 7:14 The environmental cost of AI no one talks about 9:18 Finding the balance between innovation and human survival 13:06 Advice for listeners: don't wait on the sidelines 📲 Enjoyed this episode? 👉 Like, Subscribe & hit the 🔔 to never miss a Pharma Talks episode 👉 Want to be a guest? Plan your recording with Nataliya Andreychuk at NEXT Pharma Summit (Dubrovnik) 🔗 Follow & Connect: 🎙️ Nataliya Andreychuk → https://www.linkedin.com/in/andreychuk/ 🎙️ Karol Wolak → https://www.linkedin.com/in/karolwolak/
Agentic AI has moved pharma from answering questions to autonomously orchestrating entire workflows — but most organisations are still building the foundations it needs to run well. In this episode, Nataliya Andreychuk talks with Michal Dojlidko about what agentic AI actually requires in practice: the right data, the right guardrails, continuous upskilling, and a clear-eyed view of where humans still belong in the loop. Key topics Evolution of AI in pharma from answering questions to autonomous workflows Importance of trust and data foundations in AI adoption Regulatory considerations and human oversight in agentic AI Future roles of humans as strategists and overseers of AI Technological advancements enabling secure, scalable AI solutions Chapters 00:00 Introduction to Agentic AI in Pharma Marketing 00:55 Evolution of AI in Pharma 02:34 The Shift to Autonomous AI 03:49 Reimagining Workflows with AI 05:10 Building Trust in AI 06:23 Data Foundations for AI Success 07:47 Continuous Learning and AI Literacy 09:31 The Future Role of Humans in AI 12:19 Security and Compliance in AI 14:11 Human Oversight in Regulated Industries 15:56 Hot or Not: AI Statements 23:45 Conclusion and Key Takeaways Discover more platforms to listen to this podcast: https://rss.com/podcasts/pharma-talks/ *** Follow Viseven, Nataliya, and Michal in social media: https://www.linkedin.com/company/2907491 https://www.linkedin.com/in/andreychuk/ https://www.linkedin.com/in/mdojlidko/
Michael Kirzhner, Omnichannel Platforms and Capabilities Leader at AbbVie, joins Nataliya Andreychuk to discuss the real state of omnichannel in pharma — what the industry has built, what's still missing, and where the next evolution lies. Michael has spent over a decade navigating the shift from field-centric models to digital-first orchestration inside one of the world's largest pharma companies. In this episode: Omnichannel fragmentation starts with departments, not technology — the coordination layer is what pharma hasn't built yet Most companies are strong at functional execution but lack a central decisioning function that cuts across channels Digital opinion leaders are outpacing traditional KOLs because they've mastered the channels pharma is still learning Patient services is facing the same orchestration challenge commercial solved — and the stakes are higher AI's real value isn't automation — it's closing the gaps in personalization, decisioning, and content throughput that were previously impossible at scale 📲 Enjoyed this episode? 👉 Like, Subscribe & hit the 🔔 to never miss a Pharma Talks episode 👉 Want to be a guest? Plan your recording with Nataliya Andreychuk at NEXT Pharma Summit (Dubrovnik) 🔗 Follow & Connect: 🎙 Nataliya Andreychuk → https://www.linkedin.com/in/andreychuk/ 🎙 Michael Kirzhner → https://www.linkedin.com/in/michaelkirzhner/
In this episode of Pharma Talks, recorded live at NEXT Pharma Summit in Dubrovnik, Nataliya Andreychuk speaks with Jennifer Cleall, Global Head of Digital Transformation at Ferring Pharmaceuticals, on what it actually takes to align medical and commercial teams — and where AI fits into that picture. Jennifer brings cross-industry perspective spanning pharma, med tech, and enterprise technology. Key takeaways: AI won't take our jobs — but being deliberate about where and why you apply it is what separates progress from noise Before layering in AI, organizations need to simplify processes and systems first — technology won't fix broken foundations AI can act as an enabler for medical-commercial alignment, but directional clarity on where you're headed has to come first The goal hasn't changed: showing up with relevance and trust for HCPs to improve patient outcomes Digitizing what exists today is not the destination — the real question is where pharma needs to be in five to ten years 📲 Enjoyed this episode? 👉 Like, Subscribe & hit the 🔔 to never miss a Pharma Talks episode 👉 Want to be a guest? Plan your recording with Nataliya Andreychuk: https://www.linkedin.com/in/andreychuk/
In this episode Laragh De Bhulbh shares her expertise on breaking down silos within pharma organizations, fostering cross-functional collaboration, and implementing strategic frameworks to enhance medical affairs. Discover practical tips for leaders and the importance of trust, communication, and strategic alignment in driving patient impact. Key topics: - Cross-functional collaboration challenges in pharma - The Catalyst framework for alignment - Leadership strategies for medical affairs - The role of trust and communication Chapters 00:00 Introduction to Laragh De Bhulbh and her expertise 01:24 Lara's background and motivation for improving pharma collaboration 02:21 The evolution of medical affairs and organizational alignment 03:27 Challenges in integrating medical and commercial functions 06:10 Overcoming silos: trust, safety, and open communication 10:04 The Catalyst framework: eight pillars for cross-functional success 12:42 The importance of omnichannel communication and rapid pivoting 15:59 Leadership tips for fostering collaboration and strategic clarity 17:43 Quick reactions: what is hot or not in pharma collaboration 19:18 Final thoughts: clarity and communication as game changers Discover more platforms to listen to this podcast: https://rss.com/podcasts/pharma-talks/ *** Follow Viseven, Nataliya, and Laragh in social media: https://www.linkedin.com/company/2907491 https://www.linkedin.com/in/andreychuk/ https://www.linkedin.com/in/ldeb/
In this episode of Pharma Talks, recorded live at NEXT Pharma Summit in Dubrovnik, Nataliya Andreychuk speaks with Michael Kurr, a global transformation leader with 15+ years building large-scale commercial and medical affairs operations at Novartis and Boehringer Ingelheim, on what delivery at scale actually looks like in the AI era. Michael built content and delivery organizations of over 1,000 people — and he has some of the most direct takes on where pharma transformation is stalling. Key takeaways: Modular content served its purpose as a scalability crutch — but well-trained AI models will eventually make it obsolete MLR is a bottleneck not just because of technology, but because of trust — local approvers carry legal liability and need confidence in what they sign off AI systems must become more explainable and deterministic before pharma can rely on AI-generated and AI-approved content The King Kong principle: having content is the easier part — getting the right content to the right customer at the right time, at scale, is the real challenge Staying relevant and staying current is the only viable strategy for individuals navigating AI-driven transformation 📲 Enjoyed this episode? 👉 Like, Subscribe & hit the 🔔 to never miss a Pharma Talks episode 👉 Want to be a guest? Plan your recording with Nataliya Andreychuk at NEXT Pharma Summit (Dubrovnik) 🔗 Follow & Connect: 🎙️ Nataliya Andreychuk → https://www.linkedin.com/in/andreychuk/ 🎙️ Michael Kurr → https://www.linkedin.com/in/michaelkurr/
In this episode of Pharma Talks, recorded live at NEXT Pharma Summit in Dubrovnik, Nataliya Andreychuk speaks with Lauren Leahy, who leads global and international medical capabilities operations, on what AI really means for the people working inside pharma today. Lauren brings a medical affairs perspective to a conversation that's usually dominated by commercial voices. Key takeaways: AI isn't eliminating jobs — but it is fundamentally changing how they're structured and what skills they demand In omnichannel, AI is actually increasing workload in the short term as teams redesign processes and upskill The real opportunity isn't just productivity gains — it's system-level change and improved output quality Medical and commercial functions need to work closer together around a single customer experience Staying curious and adaptable — at both individual and company level — is the core competency for navigating what's ahead 📲 Enjoyed this episode? 👉 Like, Subscribe & hit the 🔔 to never miss a Pharma Talks episode 👉 Want to be a guest? Plan your recording with Nataliya Andreychuk 🔗 Follow & Connect: 🎙️ Nataliya Andreychuk → https://www.linkedin.com/in/andreychuk/
In this episode of Pharma Talks, recorded live at NEXT Pharma Summit in Dubrovnik, Nataliya Andreychuk sits down with Laetitia Huret, Lead of Transformation at Servier, to explore what AI-driven commercial excellence actually looks like on the ground. Laetitia Huret works across global-to-local transformation, helping teams navigate digital, data, and AI change in the sales and commercial space. Key takeaways: The real question isn't whether AI will replace jobs — it's whether we're willing to keep ways of working that can be replaced AI's value in pharma lies in augmenting HCP engagement, not just accelerating content volume Human experience and accumulated knowledge remain the irreplaceable edge in an AI-assisted environment Embracing agentic and generative AI tools requires genuine investment in understanding them — not expecting magic Those not actively adopting AI risk falling behind in an industry-wide shift already underway 📲 Enjoyed this episode? 👉 Like, Subscribe & hit the 🔔 to never miss a Pharma Talks episode 👉 Want to be a guest? Plan your recording with Nataliya Andreychuk 🔗 Follow & Connect: 🎙️ Nataliya Andreychuk → https://www.linkedin.com/in/andreychuk/
Watch the first part of the conversation: https://youtu.be/PtR62juQ4FY This episode Nataliya Andreychuk with guests explores the impact of AI on pharma marketing and communication, emphasizing the importance of human oversight, regional differences in Asia, and practical strategies for global-to-local adaptation. 👥 Guests in this episode: Bruno Senouci - co-CEO at DRCOM Gwenael Meneux - co-CEO at DRCOM Key Topics: AI impact on pharma communication Regional differences in Asia healthcare markets Global to local content adaptation strategies Contact Viseven experts to elevate your healthcare marketing strategy: https://viseven.com/contact-us/ Follow Viseven and Nataliya, Bruno and Gwenael in social media: https://www.linkedin.com/in/andreychuk/ https://www.linkedin.com/in/bsenouci/ https://www.linkedin.com/in/gwenael-meneux/?locale=fr
Watch the second part of the conversation: https://youtu.be/9wQPF4W6qNQ This episode Nataliya Andreychuk with guests explores the impact of AI on pharma marketing and communication, emphasizing the importance of human oversight, regional differences in Asia, and practical strategies for global-to-local adaptation. 👥 Guests in this episode: Bruno Senouci - co-CEO at DRCOM Gwenael Meneux - co-CEO at DRCOM Key Topics: AI impact on pharma communication Regional differences in Asia healthcare markets Global to local content adaptation strategies Follow Viseven and Nataliya, Bruno and Gwenael in social media: https://www.linkedin.com/in/andreychuk/ https://www.linkedin.com/in/bsenouci/ https://www.linkedin.com/in/gwenael-meneux/?locale=fr
In this episode recorded live at the Reuters event in Barcelona, Nataliya Andreychuk sits down with Vanitha Venkatasubramaniam, Associate Director at Novo Nordisk, for an honest conversation about where pharma stands today with AI — and where the real opportunity lies ahead. Vanitha brings a refreshingly balanced view: the skills aren't fully there yet, but the intention from leadership is. And the most exciting work? Using AI to genuinely improve the experience for HCPs and patients. Key takeaways: AI adoption in pharma is accelerating faster than most teams are ready for Leadership intent is strong — but building the right skills across teams remains the gap Generative AI is already embedded in day-to-day workflows — Copilot, emails, meetings The biggest opportunity is using AI to enhance experiences for HCPs and patients, not just internal efficiency Think beyond existing marketing models — combine them with technology to create innovative go-to-market approaches 📲 Enjoyed this episode? 👉 Like, Subscribe & hit the 🔔 to never miss a Pharma Talks episode 👉 Want to be a guest? Plan your recording with Nataliya Andreychuk at NEXT Pharma Summit (Dubrovnik)
In this episode recorded live at the Reuters event in Barcelona, Nataliya Andreychuk sits down with Maryna Alexeychuk, Head of Strategic Accounts at Viseven, for a grounded take on what AI in pharma marketing should actually look like in practice. Her message is clear: AI shouldn't be a separate initiative — it should live inside the tools and processes marketers already use every day. Key takeaways: AI should be embedded where marketers already work — content, campaigns, reporting Contextual, always-on AI beats standalone tools nobody opens twice AI won't replace pharma marketers — human context in engagement is irreplaceable Before choosing a technology, map your end-to-end processes and define your goal first 📲 Enjoyed this episode? 👉 Like, Subscribe & hit the 🔔 to never miss a Pharma Talks episode 👉 Want to be a guest? Plan your recording with Nataliya Andreychuk at NEXT Pharma Summit (Dubrovnik)
In this episode, host Nataliya Andreychuk sits down with three industry experts for honest, unfiltered conversations about how AI is reshaping the pharmaceutical industry — from content supply chains to market access and beyond. 👥 Guest in this episode: Marc Koolen - Omnichannel Head GSK Follow Viseven and Nataliya and Marck in social media: https://www.linkedin.com/in/andreychuk/ https://www.linkedin.com/in/marc-koolen/
In this episode recorded live at the Reuters event in Barcelona, Nataliya Andreychuk sits down with Haider Alleg, pharma strategist turned venture capitalist at Allegory Capital, to explore why AI in pharma commercial operations is still mostly noise — and what it will actually take to change that. With 20 years in pharma and a fresh perspective from the VC world, Haider cuts through the hype and makes a bold claim: this isn't a technology shift. It's a culture shift. Key takeaways: AI in R&D and manufacturing is already mature — commercial operations are just catching up Dark factories and agentic systems show what full automation can look like The biggest opportunity isn't automating tasks — it's re-internalizing operational work with AI Medical and scientific affairs are best positioned to lead the way right now The advice that matters most: get your hands dirty and stay curious 📲 Enjoyed this episode? 👉 Like, Subscribe & hit the 🔔 to never miss a Pharma Talks episode 👉 Want to be a guest? Plan your recording with Nataliya Andreychuk at NEXT Pharma Summit (Dubrovnik) 🔗 Follow & Connect: 🎙️ Nataliya Andreychuk → https://www.linkedin.com/in/andreychuk/ 🎙️ Haider Alleg → https://www.linkedin.com/in/haideralleg/
Ranking source
Apple Podcasts rankings via the Mato Topic Intelligence Platform.
Observed September 11, 2026. Cached outside the daily freshness window; the positions keep the date they were taken on.
Apple and Apple Podcasts are trademarks of Apple Inc., registered in the U.S. and other countries.
Pairs with
Bring this source into Mato to read its transferable patterns, then turn them into an original show for your own audience.